Samsung Bioepis Archives | Page 2 of 3

Home / Posts tagged Samsung Bioepis (Page 2)

Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab)

INCHEON, Korea and TORONTO, March 10 (Korea Bizwire) — Samsung Bioepis Co., Ltd. and Biogen Canada Inc. today announced that Health Canada has approved BYOOVIZ™ – a biosimilar referencing LUCENTIS®i (ranibizumab) – for the treatment of neovascular (wet) age-related macular degeneration (AMD); visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), [...]

Samsung Bioepis Celebrates 10 Years of Realizing Passion for Health, Innovating Patients Access Worldwide

INCHEON, Korea, Feb. 28 (Korea Bizwire) – Samsung Bioepis Co. Ltd. today celebrated its 10th anniversary of its establishment by reflecting the past, present and the future of its passion for health in increasing patient access to quality biologic medicines. The company held a virtual ceremonial event to mark the company’s anniversary with its global employees. “I [...]

Global Sales of Samsung Bioepis’ 5 Biosimilars Jump 11 pct in 2021

SEOUL, Feb. 18 (Korea Bizwire) — Samsung Bioepis Co., a South Korean biopharmaceutical company, said Friday that global sales of its five biosimilar products, outside of the South Korean market, jumped 11 percent on-year in 2021. The combined sales of the five biosimilars — Infliximab, Etanercept, Adalimumab, Trastuzumab and Bevacizumab — came to around US$1.25 [...]

Canadian Authorities Approve Samsung Bioepis’ Ontruzant

SEOUL, Feb. 3 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Thursday it has won approval from Canadian authorities for the sale of its biosimilar cancer drug Ontruzant. The Health Canada has approved Ontruzant — a biosimilar product referencing Switzerland-based Roche Holding’s Herceptin, also known as Trastuzumab — for treatment of adults [...]

Samsung Biologics to Acquire Biogen’s Entire Stake in Samsung Bioepis for US$2.3 bln

SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday that it has reached a deal with Biogen Inc. to buy the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 billion. Currently, Biogen owns 50 percent minus one share in Samsung Bioepis, the joint venture [...]

Samsung Bioepis Gets Nod for Sale of Ophthalmology Biosimilar Drug in Europe

SEOUL, Aug. 23 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Monday it has won approval from European authorities for the sale of its ophthalmology biosimilar, Byooviz. The European Commission granted the marketing authorization on ranibizumab biosimilar, previously known as SB11, which references Swiss pharmaceutical giant Novartis’ blockbuster medication Lucentis. It is [...]

Global Sales of Samsung Bioepis’ Biosimilars Up 30 pct in H1

SEOUL, Aug. 13 (Korea Bizwire) — South Korean drugmaker Samsung Bioepis Co. said Friday that global sales of its five biosimilar products jumped 30 percent on-year during the first half of the year. Combined sales of the five biosimilars — Infliximab, Etanercept, Adalimumab, Trastuzumab, Bevacizumab — came to US$166 million in the January-June period, compared [...]

Samsung Bioepis Opens the New State-of-the-Art Headquarters to Accommodate Next Stage of Growth and Innovation

INCHEON, Korea, Jan. 25 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today announced the opening of its new headquarters in Korea’s ‘Bio Cluster’ of Songdo, located in the Incheon Free Economic Zone (IFEZ), a specially-designated economic zone in the city of Incheon. The new site is approximately 52,000 square feet, and will be the hub [...]

Samsung Bioepis Gets Nod for Sale of Anticancer Biosimilar Drug in Europe

SEOUL, Aug. 21 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. said Friday it has won approval from European authorities for the sale of its anticancer biosimilar drug, Aybintio. The European Commission (EC) accepted Samsung Bioepis’ application to sell the bevacizumab biosimilar, also known as SB8, which references Switzerland-based Roche Holding’s blockbuster pill [...]

Samsung Bioepis’ Ophthalmology Biosimilar Candidate Receives Clinical Approvals in 8 Markets

SEOUL, June 15 (Korea Bizwire) — South Korean pharmaceutical firm Samsung Bioepis Co. said Monday that it has won approvals in major countries to conduct clinical trials for its new ophthalmology biosimilar candidate. SB15 is a biosimilar candidate referencing Regeneron Pharmaceuticals Inc.’s Eylea, a blockbuster therapy to treat age-related (wet) macular degeneration (AMD). It is [...]